Formulation and stability evaluation of an extemporaneously prepared baclofen suspension (1 mg/mL)

被引:2
作者
Purohit, Trusha J. [1 ]
Thakur, Sachin S. [1 ]
Carruth, Jonathan [1 ]
Dean, Farhan [1 ]
Kim, Darin [1 ]
Lee, Seunghyun [1 ]
Liu, Colin [1 ]
Sharma, Manisha [1 ]
Hanning, Sara M. [1 ]
机构
[1] Univ Auckland, Sch Pharm, 85 Pk Rd, Auckland 1010, New Zealand
关键词
paediatrics; formulation; stability; baclofen; extemporaneous compounding;
D O I
10.1002/jppr.1750
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background Baclofen is prescribed for both adults and children as a muscle relaxant, but no data exists to support an appropriate lower-dose extemporaneously compounded oral liquid suitable for young children in New Zealand. Aim This study aimed to determine the stability of 1 mg/mL baclofen oral suspension over 30 days. Method Baclofen suspensions were compounded (n = 6 per formulation) using suspending vehicles Ora-Blend(R) (OB) or Ora-Blend sugar-free(R) (OB SF) and stored at either 25 degrees C/60% relative humidity or 2-8 degrees C for 30 days. Organoleptic properties, sedimentation volume ratio, ease of redispersion, pH and baclofen content were determined. Results Formulations required 2-3 inversions to redisperse at each time point. A colour change was observed from day 14 in the OB suspensions stored at both temperatures, likely due to the Maillard reaction, whereas no colour change was observed in any OB SF suspensions. The pH of all formulations remained between 4.5 and 4.6. Both OB and OB SF suspensions retained >90% of the initial baclofen concentration over 30 days. Conclusion Although baclofen 1 mg/mL suspensions prepared in both OB and OB SF retained sufficient baclofen to be considered chemically stable in both storage conditions over the study period, OB SF is recommended as a preferred vehicle over OB formulations due to the colour change observed.
引用
收藏
页码:314 / 320
页数:7
相关论文
共 22 条
  • [1] Amlodipine besylate-excipients interaction in solid dosage form
    Abdoh, A
    Al-Omari, MM
    Badwan, AA
    Jaber, AMY
    [J]. PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY, 2004, 9 (01) : 15 - 24
  • [2] Stability of baclofen, captopril, diltiazem hydrochloride, dipyridamole, and flecainide acetate in extemporaneously compounded oral liquids
    Allen, LV
    Erickson, MA
    [J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 1996, 53 (18) : 2179 - 2184
  • [3] [Anonymous], 1995, ICH Topic Q2 (R1) - Validation of Analytical Procedures: Text and Methodology
  • [4] Formulations for children: problems and solutions
    Batchelor, Hannah K.
    Marriott, John F.
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2015, 79 (03) : 405 - 418
  • [5] Falconer JR, 2017, AUST PRESCR, V40, P5, DOI 10.18773/austprescr.2017.001
  • [6] Florey K., 1985, ANAL PROFILES DRUG S, V14, P527, DOI [DOI 10.1016/S0099-5428(08)60590-0, 10.1016/S0099-5428(08)60590-0]
  • [7] Review of the physicochemical methods applied in the investigation of the maillard reaction in pharmaceutical preparations
    Ghaderi, Faranak
    Monajjemzadeh, Farnaz
    [J]. JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, 2020, 55
  • [8] Liquid Dosage Forms Extemporaneously Prepared from Commercially Available Products - Considering New Evidence on Stability
    Haywood, Alison
    Glass, Beverley D.
    [J]. JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES, 2013, 16 (03): : 441 - 455
  • [9] Assessment of Feasibility of Maillard Reaction between Baclofen and Lactose by Liquid Chromatography and Tandem Mass Spectrometry, Application to Pre Formulation Studies
    Monajjemzadeh, Farnaz
    Hassanzadeh, Davoud
    Valizadeh, Hadi
    Siahi-Shadbad, Mohammad R.
    Mojarrad, Javid Shahbazi
    Robertson, Thomas
    Roberts, Michael S.
    [J]. AAPS PHARMSCITECH, 2009, 10 (02): : 649 - 659
  • [10] Mylan New Zealand, 2020, NZ DAT SHEET PAC MYL